What Is Calcitonin? The Thyroid Hormone With No Clear Job

Peptide science

Calcitonin is a 32-amino-acid hormone from the thyroid that lowers blood calcium, was discovered in the wrong gland, and — sixty years later — still has no clearly established job in adult human calcium balance. That is not a hedge. When the gene is deleted in mice, bone mass goes up. Patients with medullary thyroid carcinoma run wildly abnormal calcitonin levels and have no skeletal disease. One 2015 review noted that calcitonin no longer even merits a chapter in the standard bone-disease primer. It is one of the most instructive peptides in endocrinology precisely because the tidy textbook story falls apart when you check it.

What is calcitonin?

Calcitonin was named by Copp and colleagues in 1962 in a paper whose title preserves the original error: “Calcitonin — a Hormone from the Parathyroid which Lowers the Calcium-level of the Blood.” They had perfused isolated thyroid-parathyroid preparations in anaesthetised dogs and correctly identified a calcium-lowering factor, but attributed it to the wrong gland.

The correction came in 1963 from Hirsch, Gauthier and Munson at Harvard, with an experiment that is a small masterpiece of design. Rats parathyroidectomised by hot-wire cautery showed a much steeper fall in serum calcium than rats parathyroidectomised by excision. Burning the gland released something the scalpel did not. They named it thyrocalcitonin and explicitly discussed its relationship to Copp’s “calcitonin.” A thyroid origin was confirmed the following year, and the source was pinned to the thyroid C cells by 1966. The two surviving names are the fossil record of that argument.

Structurally, calcitonin is compact and highly conserved in its ends. The human precursor is 141 residues; the mature hormone is 32 amino acids with a disulfide bridge between cysteine 1 and cysteine 7 and a proline amide at the C-terminus. Those two features are shared across every species in which the structure has been determined; the divergence sits in the interior, roughly residues 10 to 27.

One gene, two hormones — and a sepsis marker

The CALCA gene sits on chromosome 11, and in 1982 Amara and colleagues showed in Nature that alternative processing of its RNA transcripts produces distinct mRNAs encoding either calcitonin or a predicted product they called calcitonin gene-related peptide. Calcitonin mRNA predominates in the thyroid; the CGRP-specific mRNA predominates in the hypothalamus. This was a landmark result — the model they proposed, that developmental regulation of RNA processing increases the diversity of neuroendocrine gene expression, is now textbook.

The practical consequence is that calcitonin and CGRP are siblings with nothing functionally in common. One nudges osteoclasts; the other is a potent vasodilator and the target of an entire class of migraine drugs. The same locus also yields katacalcin, a 21-residue C-terminal fragment reported in 1983 as a calcium-lowering peptide in its own right — a claim worth treating as a 1983 claim rather than settled fact.

And then there is procalcitonin, which readers conflate with calcitonin constantly. Procalcitonin is the 116-residue intermediate — the 141-residue precursor minus its 25-residue signal sequence. Under normal conditions thyroid C cells process it onward to calcitonin, so serum procalcitonin sits below 0.05 ng/mL. In bacterial infection, liver, pancreas, kidney, lung, intestine and leukocytes synthesise procalcitonin — up to 100- to 1,000-fold more — and do not process it further. That is the sepsis marker. It has a half-life of 20 to 24 hours and tells you nothing about calcium.

How calcitonin is studied to work

Calcitonin signals through the calcitonin receptor, a class B G-protein-coupled receptor that activates adenylate cyclase and raises cAMP, with phospholipase C and IP3 involvement as well. If you want the general mechanics, see our primer on what a GPCR is.

In bone, the documented effect is on osteoclasts, not osteoblasts. Calcitonin prompts osteoclast contraction, reducing their motility and their capacity to resorb bone; it inhibits carbonic anhydrase II, disrupting the acidic microenvironment osteoclasts need; and it hinders differentiation of osteoclast precursors. Two distinct effects have been described in the isolated-osteoclast literature — quiescence (loss of motility) and retraction (the cell physically pulling back) — and they appear to run through separate post-receptor routes.

In the kidney, injectable salmon calcitonin increases excretion of filtered phosphate, calcium and sodium by decreasing their tubular reabsorption. There is also a neat spatial detail: calcitonin stimulates 1,25-dihydroxyvitamin D production in the proximal straight tubule, while parathyroid hormone and phosphorus do so in the proximal convoluted tubule.

Secretion is the mirror image of PTH. Both are controlled by the calcium-sensing receptor, but activating it suppresses PTH and stimulates calcitonin. There is an asymmetry worth noting: virtually every human and animal mounts a PTH response to hypocalcaemia, yet a number of humans and animals fail to produce any calcitonin response to hypercalcaemia at all. Compare with our overview of the parathyroid glands and calcium homeostasis.

The receptor family is where calcitonin stops looking like a historical curiosity. Two genes — CALCR for the calcitonin receptor and CALCRL for the calcitonin receptor-like receptor — combine with three receptor activity-modifying proteins to produce receptors for six endogenous peptides: calcitonin, alpha- and beta-CGRP, amylin, adrenomedullin and adrenomedullin 2. On its own, CLR binds no known endogenous ligand at all; the RAMP decides what it becomes.

The awkward part: what happens when calcitonin is missing

Here is where the textbook version breaks. In a knockout mouse with the calcitonin gene deleted, there were no developmental defects and normal reproduction. Trabecular bone volume and bone formation were increased at one and three months. Baseline serum calcium was unaffected. Female knockouts even appeared protected against ovariectomy-induced bone loss. Deleting the hormone that inhibits bone resorption made the bones better.

The human data point the same way. No bone or other abnormalities have been described in calcitonin deficiency or excess, apart from diarrhoea in some patients with medullary thyroid carcinoma. Thyroidectomised patients who lose bone do so because of inadequate thyroid hormone replacement, not the absence of calcitonin. Patients with grossly elevated calcitonin from medullary carcinoma show no skeletal changes.

Why the drug is salmon calcitonin

Every marketed calcitonin product is the salmon sequence, and the reason is pharmacological rather than economic. Salmon calcitonin-1 is also 32 residues with the same Cys1-Cys7 ring and C-terminal prolinamide, but 16 of its 32 positions differ from the human peptide. The FDA label states that its actions are essentially identical to mammalian calcitonins “but its potency per mg is greater and it has a longer duration of action.” Notably, the label gives no multiplier — and neither do the reviews, which say only that non-mammalian calcitonins have the greatest potency. Treat any specific fold-figure you see online with suspicion.

The pharmacokinetics are modest: absolute bioavailability about 66% intramuscular and 71% subcutaneous, peak plasma levels around 23 minutes after subcutaneous dosing, and a terminal half-life of roughly 58 to 64 minutes. There is also a nice evolutionary argument in the literature — calcitonin is phylogenetically older than PTH, evolving in ocean fish that needed to expel calcium, while PTH arose in land animals that needed to conserve it.

Escape, antibodies and tachyphylaxis

Calcitonin is one of the cleanest worked examples of loss of response over time, and it involves at least three separate mechanisms that are routinely lumped together. Our guide to tachyphylaxis, tolerance and downregulation covers the distinctions in general; calcitonin supplies all three.

• Osteoclast escape (cellular, hours). Osteoclasts undergo retraction and escape the sustained effects of calcitonin within 24 to 48 hours. This is the rapid clinical escape seen when treating hypercalcaemia, and it is not immunological.
• Neutralising antibodies (immunological, months). Circulating antibodies to salmon calcitonin appeared after 2 to 18 months of treatment in about half of Paget’s disease patients studied, and high titres usually meant loss of response. In one series of 85 patients, 22 reverted to baseline biochemistry despite continued treatment — and 19 of those 22 had elevated antibody titres.
• C-cell depletion (endocrine). Chronic hypercalcaemia reduces thyroid calcitonin content and blunts the response to acute calcium stimulation, while basal serum calcitonin stays unchanged.

Neither FDA label uses the word “tachyphylaxis”; both frame it as antibody-mediated loss of response. That framing is incomplete.

The 2012-2013 regulatory split

Two regulators looked at the same data and reached different conclusions, which makes this one of the more interesting case studies in benefit-risk assessment.

The European review was triggered by preliminary findings from two studies of an unlicensed oral calcitonin product suggesting a possible association with prostate cancer, made available to national authorities in November 2010. The CHMP completed its review in July 2012, confirmed it on re-examination in November, and the European Commission decision followed on 13 February 2013. Reported cancer-rate increases ranged from 0.7% in oral-formulation studies to 2.4% in nasal studies. Because the nasal spray was used only for osteoporosis — where the benefit was judged limited — the CHMP recommended that formulation no longer be used at all. What survived in the EU was injection and infusion, restricted to short courses for acute immobilisation bone loss, Paget’s disease unresponsive to alternatives, and cancer-related hypercalcaemia.

The United States kept all three indications, including a marketed nasal spray, but rewrote the labelling: osteoporosis treatment “when alternative treatments are not suitable,” an explicit statement that fracture reduction efficacy has not been demonstrated, and a limitation of use requiring periodic re-evaluation because of the possible malignancy association.

The meta-analysis behind all of this is printed in full on the label: 21 randomised controlled trials, 10,883 patients, malignancies in 4.1% of calcitonin-treated versus 2.9% of placebo patients, and 4.5% versus 2.3% in the nasal-spray-only subset. But the label is unusually candid about the limits — the increased risk was “heavily influenced by a single large 5-year trial,” “a mechanism for these observations has not been identified,” and “a definitive causal relationship between calcitonin salmon use and malignancies cannot be established from this meta-analysis.” Two of the four adjusted risk-difference estimates cross zero. The regulatory action was a judgement about weak efficacy meeting an uncertain signal, not a demonstration of carcinogenicity.

Calcitonin as a tumour marker

The hormone found its most durable clinical use as a marker rather than a drug. Medullary thyroid carcinoma arises from the C cells themselves, so it makes calcitonin. It accounts for only 1% to 5% of thyroid cancers but around 13% of thyroid-cancer mortality, and about 75% of cases are sporadic. Because the tumour secretes the hormone, calcitonin is a valuable marker for monitoring tumour growth and recurrence — though it is not specific enough for diagnosis on its own, since calcitonin can be falsely elevated in other conditions. The classic symptoms of very high circulating calcitonin are diarrhoea and flushing, which is exactly the one clinical abnormality reviews attribute to calcitonin excess.

Where the calcitonin family shows up now

The receptor family has outlived the hormone’s own therapeutic career. Cagrilintide, the long-acting amylin analogue in obesity development, is classified in the peer-reviewed literature as a dual amylin and calcitonin receptor agonist — it engages the calcitonin receptor too. A competing preclinical class is built on a salmon calcitonin backbone outright. Both are rat and cell-based data, and the main comparative paper comes from a company that owns one of the compounds, so read it with that in mind. The structural point stands regardless: a 1962 bone hormone is embedded in current metabolic drug design. You can find cagrilintide and related compounds in our peptide library.

Frequently asked questions

Is calcitonin the opposite of parathyroid hormone?

In secretion control, yes — both are governed by the calcium-sensing receptor, and activating it suppresses PTH while stimulating calcitonin. In importance, no. PTH deficiency causes obvious disease; calcitonin deficiency does not. The honest summary is that calcitonin buffers acute calcium loads and probably matters in lactation, but is not a co-equal partner in day-to-day adult calcium regulation.

Does calcitonin build bone?

Its verified action is inhibition of osteoclast resorption, not stimulation of osteoblasts. The claim that calcitonin drives osteoblasts to deposit calcium is a textbook simplification that the knockout-mouse data contradict directly — deleting the gene increased trabecular bone volume and bone formation.

Was calcitonin banned for causing cancer?

No, on both counts. The EU withdrew the nasal spray and restricted injectable use; the US retained all three indications with tightened wording and a periodic re-evaluation requirement. And the FDA label explicitly states no mechanism has been identified and causation cannot be established from the meta-analysis. It was a benefit-risk decision against a drug whose fracture-reduction benefit had not been demonstrated.

Is procalcitonin a type of calcitonin?

They come from the same gene and the same precursor, but they are used for entirely unrelated things. Procalcitonin is the unprocessed 116-residue intermediate; in bacterial infection, non-thyroid tissues make large amounts of it and never convert it. A high procalcitonin is a sepsis signal, not a calcium signal.

Informational only — not medical advice · 21+